Abstract
Major finding: CRAF has a direct role in mitosis that does not require the RAF effector MEK.
Mechanism: CRAF interacts with PLK1 and promotes its activity and accumulation at kinetochores.
Impact: Allosteric RAF inhibitors that block phospho-Ser338 CRAF may be effective cancer therapies.
This content is only available via PDF.
©2011 American Association for Cancer Research.
2011